It was a pleasure to speak with Sara Bares (University of Nebraska, Omaha, NE, USA) to discuss long-acting injectable antiretroviral therapies for the treatment of HIV.
The abstract entitled: ‘Long Acting ART for Treatment of HIV’ was presented at the ACTHIV Virtual Conference 2021, May 20-22, 2021.
Questions:
- What are the potential advantages and disadvantages of long-acting injectable (LAI) antiretroviral therapy (ART) for the treatment of HIV, compared to current treatment regimens? (0:15)
- Could you give us a brief overview of the FLAIR & ATLAS study objectives, and their findings? (2:51)
- Which patients are most likely to benefit from this regimen and in whom is it contraindicated? (4:49)
- What are the potential considerations/ challenges providers and patients may need to bear in mind before deciding to implement this regimen? (5:26)
Disclosures: Sara Bares has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the ACTHIV Virtual Conference 2021.
